- Home
- UNH vs NVO Comparison
UNH vs NVO Comparison
Compare UNH & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNH
- NVO
- Stock Information
- Founded
- UNH 1977
- NVO 1923
- Country
- UNH United States
- NVO Denmark
- Employees
- UNH N/A
- NVO N/A
- Industry
- UNH Medical Specialities
- NVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UNH Health Care
- NVO Health Care
- Exchange
- UNH Nasdaq
- NVO Nasdaq
- Market Cap
- UNH 545.0B
- NVO 530.0B
- IPO Year
- UNH 1984
- NVO N/A
- Fundamental
- Price
- UNH $600.69
- NVO $105.28
- Analyst Decision
- UNH Strong Buy
- NVO Strong Buy
- Analyst Count
- UNH 20
- NVO 6
- Target Price
- UNH $606.32
- NVO $139.33
- AVG Volume (30 Days)
- UNH 3.1M
- NVO 6.5M
- Earning Date
- UNH 01-10-2025
- NVO 11-06-2024
- Dividend Yield
- UNH 1.40%
- NVO 1.37%
- EPS Growth
- UNH N/A
- NVO 26.84
- EPS
- UNH 15.38
- NVO 3.17
- Revenue
- UNH $393,898,000,000.00
- NVO $40,469,178,712.00
- Revenue This Year
- UNH N/A
- NVO $25.02
- Revenue Next Year
- UNH $7.65
- NVO $20.47
- P/E Ratio
- UNH $39.05
- NVO $32.17
- Revenue Growth
- UNH 9.42
- NVO 26.15
- 52 Week Low
- UNH $436.38
- NVO $94.73
- 52 Week High
- UNH $630.73
- NVO $148.15
- Technical
- Relative Strength Index (RSI)
- UNH 55.78
- NVO 39.46
- Support Level
- UNH $576.77
- NVO $99.42
- Resistance Level
- UNH $630.73
- NVO $107.79
- Average True Range (ATR)
- UNH 12.72
- NVO 1.96
- MACD
- UNH 0.06
- NVO -0.10
- Stochastic Oscillator
- UNH 60.64
- NVO 43.09
About UNH UnitedHealth Group Incorporated (DE)
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
About NVO Novo Nordisk A/S
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.